Trial record 1 of 10 for:
EXCITE ISR
Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis (EXCITE ISR)
This study is currently recruiting participants.
Verified April 2012 by Spectranetics Corporation
Sponsor:
Spectranetics Corporation
Information provided by (Responsible Party):
Spectranetics Corporation
ClinicalTrials.gov Identifier:
NCT01330628
First received: April 4, 2011
Last updated: April 26, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the safety and efficacy of laser atherectomy with balloon angioplasty compared to balloon angioplasty alone in the treatment of above the knee peripheral artery in-stent restenosis.
| Condition | Intervention | Phase |
|---|---|---|
|
Peripheral Arterial Disease |
Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters Procedure: Balloon angioplasty |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis |
Resource links provided by NLM:
Further study details as provided by Spectranetics Corporation:
Primary Outcome Measures:
- Target lesion revascularization (TLR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Major Adverse Events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]death, amputation, target lesion revascularization
Secondary Outcome Measures:
- Procedural success [ Time Frame: (day 1) During the interventional procedure in catheterization laboratory. Procedure may last 1-2 hours. ] [ Designated as safety issue: No ]Defined as a ≤30% stenosis in the target lesion immediately post assigned treatment
- Target vessel revascularization [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
- Primary patency [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]The proportion of subjects, with uninterrupted (intervention-free) patency since the initial procedure. Primary patency ends at the first occurrence of one of the following: reintervention for the purpose of treating the target lesion, total occlusion of the target lesion, surgical bypass of the target, or amputation of the extremity due to target lesion restenosis or occlusion.
- Assisted primary patency [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]Defined as a re-intervention of a stenosis (patent vessel) >50% at the treatment site to prevent reocclusion by angiographic assessment in the target lesion.
- Assisted secondary patency [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]Defined as a re-intervention of a reocclusion (non-patent vessel) at the treatment site by angiographic assessment in the target lesion.
- Ankle/Brachial Index (ABI) [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]
- Functional status [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]The Walking Impairment Questionnaire (WIQ) at 30 day follow up will be considered baseline and will be compared to the WIQ at 6 and 12 months.
- Rutherford classification [ Time Frame: 1, 6, and 12 months ] [ Designated as safety issue: No ]
- Stent integrity [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 353 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Laser atherectomy and PTA
laser, then balloon angioplasty
|
Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters
application of laser energy to remove blockage followed by standard balloon angioplasty
|
| Active Comparator: Balloon angioplasty |
Procedure: Balloon angioplasty
standard balloon catheters for PTA
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- PAD with Rutherford class 1-4
- Resting ABI <0.9 or abnormal exercise ABI <0.9
- History of previous femoropopliteal nitinol stenting
- Angiographic significant restenosis (>=50%)
- Target lesion length >=4 cm; no more than 3 cm outside stent at either end
- Vessel diameter >=5 mm and <=7 mm
- At least one widely patent tibial or peroneal artery to the foot
Exclusion Criteria:
- Patient is pregnant or breast feeding
- Evidence of acute limb ischemia
- Life expectancy <12 months
- CVA within 60 days of screening
- Myocardial infarction within 60 days of procedure
- Known allergy to contract media
- Known contraindication to aspirin, antiplatelet and anti-coagulation therapies
- Uncontrolled hypercoagulability
- Present or suspected systemic infection in target limb
- Serum creatinine >= 2.5 mg/dl unless dialysis dependent
- Previous treatment to target vessel within 3 months of study procedure
- Drug eluting stents or covered stents
- Ipsilateral and/or contralateral iliac stenosis >= 50% DS that is not successfully treated prior to index procedure or with final residual stenosis <= 30% documented by angiography
- Planned or predicted cardiovascular surgical or interventional procedures prior to completion of the 30-day follow-up
- Identification of any lesion below the target stent in the treated leg >50% that will require preplanned or predicted treatment within 30 days(prior to the 6 month follow up)
- Tibial artery containing a >50% Diameter Stenosis (DS) by visual estimate after popliteal
- Grade 4 or 5 stent fracture affecting target stent or proximal to the target stent, or where evidence of stent protrusion into the lumen is noted on angiography in 2 orthogonal views.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01330628
Show 27 Study Locations
Contacts
| Contact: Chris DeMorett | 719-447-2211 | christopher.demorett@spnc.com |
| Contact: Matthew Stark, PhD | 719-447-2409 | matthew.stark@spnc.com |
Show 27 Study LocationsSponsors and Collaborators
Spectranetics Corporation
Investigators
| Principal Investigator: | Eric J Dippel, MD | Midwest Cardiovascular Research Foundation |
More Information
No publications provided
| Responsible Party: | Spectranetics Corporation |
| ClinicalTrials.gov Identifier: | NCT01330628 History of Changes |
| Other Study ID Numbers: | D013474 |
| Study First Received: | April 4, 2011 |
| Last Updated: | April 26, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Spectranetics Corporation:
|
peripheral arterial disease in stent restenosis peripheral vascular disease |
Additional relevant MeSH terms:
|
Peripheral Arterial Disease Peripheral Vascular Diseases Atherosclerosis Arteriosclerosis |
Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013